GSK bets on pioneering cancer therapy with Adaptimmune deal Ruby Khatun Khatun9 Sept 2017 4:02 AMLONDON: GlaxoSmithKline (GSK) said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology,...